MedinCell S.A. (MDCLF)
Stock analysis · OTC · Healthcare · Biotechnology
MedinCell S.A. (MDCLF) is a publicly traded company in the Healthcare sector. Latest price: $30.26. Market cap $1.09B. Trailing PE -28.86. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About MedinCell S.A.
MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments. At the heart of its innovation is the BEPO platform, a unique technology designed for long-acting injectable drugs. This system utilizes specific proprietary copolymers alongside a compatible solvent to effectively dissolve or suspend active pharmaceutical compounds, ensuring their sustained release within the body. The company's clinical pipeline includes several notable projects: mdc-IRM, a subcutaneous injection intended for schizophrenia, which is currently undergoing late-stage (Phase III) clinical trials; mdc-CWM, an intra-articular injection formulated to alleviate pain and inflammation; and mdc-TJK, another subcutaneous injection also targeting schizophrenia, presently in preclinical evaluation. Furthermore, MedinCell's research efforts extend to numerous formulation candidates. These include subcutaneous injections like mdc-WWM for contraception, mdc-ANG for central nervous system conditions, mdc-ELK for depressive disorders, and mdc-GRT for applications in organ transplantation. The firm is also exploring perineural injection options such as mdc-CMV for anesthesia and…
Valuation
| P/E (TTM) | -28.86× |
|---|---|
| P/S (TTM) | 48.33× |
| P/B | 307.72× |
| PEG | 0.60× |
| P/FCF (TTM) | -36.41× |
| EV / EBITDA | -30.98× |
| EV / Sales | 48.05× |
| Earnings Yield | -3.32% |
| Free Cash Flow Yield | -2.75% |
Fundamentals
| Enterprise Value | $937.90M |
|---|---|
| Revenue (TTM) | $19.52M |
| Net Income (TTM) | -$31.30M |
| Free Cash Flow (TTM) | -$19.39M |
| Net Debt | -$5.38M |
| Working Capital | $76.02M |
| Gross Margin | 51.90% |
| Operating Margin | -130.65% |
| Net Margin | -160.30% |
| Return on Equity | 226.98% |
| Return on Invested Capital | -24.37% |
Peers
Recent News
- Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
- MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript
- Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
- Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
- Medincell to Participate in Upcoming Investor Conferences
Related
Browse more tickers: sitemap